View clinical trials related to C3 Glomerulopathy (C3G).
Filter by:The purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan
The aim of this trial is to evaluate the effect of avacopan treatment on renal disease activity in patients with complement component 3 glomerulopathy (C3G). Funding Source - FDA OOPD